COR · Cencora, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Aug 5, 2026TL;DR. Cencora delivered Q3 adjusted EPS of $4.48 (+12%) and raised its fiscal 2026 adjusted EPS guidance range to $17.75-$17.95 (from $17.70-$17.90), also lifting the bottom end of consolidated operating income growth guidance to 13-14% and USHS segment operating income growth to 14.5-15.5%, supported by $1B of opportunistic share repurchases and the One Oncology acquisition.
- + Raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95 (from $17.70-$17.90).
- + Raised bottom end of consolidated operating income growth guidance to 13-14% and USHS segment operating income growth to 14.5-15.5%.
- + Adjusted operating income grew 17% and adjusted EPS grew 12% in the quarter, with double-digit growth across both reportable segments.
- + One Oncology and RCA MSO platforms both performed ahead of expectations, driving strength in USHS specialty.
- − USHS revenue is now expected to track to the lower half of the 4-6% growth range, below the midpoint.
- − Pending MWI/Covetris merger would create a ~$150M operating income and ~$0.35 EPS headwind to fiscal 2027 if closed at mid-year.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COR
this stock
Cencora, Inc.
|
$57.74B | -8.5% | +9.3% | 22.5 | 2.3% |
|
MCK
Mckesson Corp
|
$101.04B | +10.0% | +3.1% | 23.3 | 2.5% |
|
CAH
Cardinal Health Inc
|
$52.08B | +11.1% | +14.2% | — | 2.9% |
|
HSIC
Henry Schein Inc
|
$9.63B | +12.3% | +5.9% | 25.2 | 6.8% |
|
EBOSY
EBOS Group Limited/ADR
|
$2.44B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COR | +0.7% | -8.4% | -3.2% | +2.9% | -8.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.9% | -7.9% | -15.3% | +2.0% | -21.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.